FHTX Stock — Foghorn Therapeutics Inc.: Cash, EV, Pipeline

Share price

$4.17

Market cap

$248.2M

Cash

$167.6M

Enterprise value

$80.6M

Balance sheet

Cash	$167.6M
Debt	$0.0M
Net cash	$167.6M
Enterprise value	$80.6M
Basic shares	58.7M shares
Fully diluted shares	92.8M shares
Fully diluted market cap	$387.1M
Cash per share	$2.86

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading FHTX daily closes…

Loading price history…

Pipeline assets

FHD-909

Phase 1 · Active Modality: Small molecule (oral)

Aliases LY4050784

Target SMARCA2 (BRM)

Partnerships Eli Lilly: co-development and co-commercialization; Lilly leads development/commercialization with Foghorn participation and 50% cost sharing until at least registrational trials; US profit share + ex-US royalties. Lilly selected FHD-909 for clinical development Feb 2024.

Indications

SMARCA4-mutated cancers, primarily NSCLC (Phase 1)

Status note Selective SMARCA2 (BRM) inhibitor. IND cleared May 2024; first patient dosed Oct 2024 in Phase 1 dose escalation. Lead program.

FHD-286

Phase 1 · Terminated Modality: Small molecule

Indications

Relapsed/refractory AML (combination with decitabine); uveal melanoma (Phase 1)

Status note Filing states the company decided to discontinue independent development in combination with decitabine in relapsed/refractory AML (Phase 1 clinical trial shut down) and independent development in uveal melanoma.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	FHD-286
Lead indication	Advanced Hematologic Malignancy
Lead phase	Phase 1
Active trials	1
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04891757	Phase 1	Active, not recruiting	Sponsor	FHTX	—	Advanced Hematologic Malignancy; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia	—
NCT07551635	Phase 2	Not yet recruiting	Collaborator	Dana-Farber Cancer Institute	—	Small Cell Lung Cancer	—
NCT07283094	Phase 1	Recruiting	Collaborator	Montefiore Medical Center	—	Acute Myeloid Leukemia; Myelodysplastic Syndrome	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Foghorn Therapeutics Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Sphera Biotech	0	-12,224	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

FHTX — Foghorn Therapeutics Inc.